home · filing · 0001493152-25-008538
8-K
filed February 27, 2025, 6:59 PM ET
ticker CNTN
CIK 0001861657
leadership
confidence high
sentiment neutral
materiality 0.55
Tharimmune announces CFO transition: Hess to depart March 26, Kim effective March 27
Canton Strategic Holdings, Inc.
CFO Thomas Hess resigned effective March 26, 2025; no disagreement with company operations or policies.
Don Kim appointed CFO effective March 27, 2025; consulting agreement at $225/hour for 12-month term.
Kim previously served as CFO of UroGen Pharma (2022-2024) and held finance roles at Strides Pharma, Sun Pharma, and Zoetis.
Kim is a licensed CPA and will serve as an independent contractor, not an employee.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2025-03-27
Filed February 27, 2025, 6:59 PM ET
appointed Don Kim as Chief Financial Officer of the Company, effective as of March 27, 2025.
Effective 2025-03-26
Successor Don Kim
Filed February 27, 2025, 6:59 PM ET
accepted the resignation of Thomas Hess as Chief Financial Officer of the Company, effective as of March 26, 2025.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Don Kim was appointed as Chief Financial Officer at Canton Strategic Holdings, Inc..
Action appointed
Role Chief Financial Officer
Exact text from the filing
appointed Don Kim as Chief Financial Officer of the Company, effective as of March 27, 2025.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Thomas Hess resigned as Chief Financial Officer at Canton Strategic Holdings, Inc..
Action resigned
Role Chief Financial Officer
Exact text from the filing
accepted the resignation of Thomas Hess as Chief Financial Officer of the Company, effective as of March 26, 2025.
View on SEC.gov
Source: SEC EDGAR
accession 0001493152-25-008538
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.